KIT and gastrointestinal stromal tumor: By comparing the gene expression profiles before and after the treatment of GIST with imatinib, it is observed that imatinib can down-regulate the PD-L1 expression by inhibiting KIT and PDGFRA, which countervails the immunosuppression of GIST [18].